• Molecular NameErtapenem
  • Synonymertapenem; MK-0826
  • Weight475.522
  • Drugbank_IDDB00303
  • ACS_NO153832-46-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.53
  • pka2.72; 3.96; 7.06
  • LogD (pH=7, predicted)-2.97
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.16
  • LogSw (predicted, AB/LogsW2.0)5.19
  • Sw (mg/ml) (predicted, ACD/Labs)3.26
  • No.of HBond Donors5
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds7
  • TPSA181.57
  • StatusFDA approved
  • AdministrationIntramuscular, intravenous
  • PharmacologyA carbapenem antibiotic marketed by Merck as Invanz.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability90.0
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMinor hydrolysis of beta-lactam ring, CYP not involved
  • Half life4 h
  • ExcretionRenal (80%) and fecal (10%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common drug-related adverse experiences in patients treated with Ertapenem were diarrhea, infused vein complication, nausea, headache, vaginitis in females, phlebitis/thrombophlebitis, and vomiting.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A